Navigation Links
Promising Data ATIR Studies Presented by NIH Investigators

AMSTERDAM, November 28 /PRNewswire/ -- Kiadis Pharma announced today the presentation of the results obtained so far in the physician initiated study led by Dr. Stephan Mielke* and Dr. John Barrett* of the National Heart, Lung, and Blood Institute (NHLBI) a department of the National Institutes of Health (NIH) on Kiadis' lead product ATIR at the AABB annual meeting & TXPO 2007 in Anaheim, California.

According to the NHLBI investigators the challenge in the field of allogeneic bone marrow transplantations lies with disease control, Graft versus Host Disease (GvHD) control and donor availability. Doctors Barrett and Mielke have focused on controlling GvHD whilst sparing the Graft versus Leukemia (GvL) effect and also on increasing donor availability.

The investigators have published the preclinical data showing promising results with Kiadis Pharma's ATIR in eliminating alloreactive T cells from donor grafts (Mielke et al. Blood, 2007). These results have led to the start of a phase II study with ATIR by the NHLBI. This trial is designed to demonstrate that ATIR treatment may overcome the need of immunosuppressant prophylaxis post transplantation. Prophylaxis is currently standard practice to prevent GvHD, but has a serious drawback, as it increases the chance of infection and also the relapse rate. Thus ATIR does not only intend to prevent GvHD, but could also reduce the rates of infection and relapse. Together, these complications account for approximately 70 % of allogeneic transplant related mortality.

For the complete press release go to


Dr John Barrett is Chief of the Allotransplant Section at National Heart, Lung, and Blood Institute (NHLBI) of National Institutes of Health (NIH) in Bethesda, MD, USA, where the trial is being performed. Dr Stephan Mielke, who initiated this study as principal investigator at NHLBI, is currently working at the Julius-Maximilians University of Wurzburg, Germany and continues as the lead associate investigator on the protocol.

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
2. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
3. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
4. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
5. Argonne researcher studies what makes quantum dots blink
6. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
7. AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies
8. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
9. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
10. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
11. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
Post Your Comments:
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Durham, NC (PRWEB) , ... June 23, 2016 , ... ... Odense University Hospital in Denmark detail how a patient who developed lymphedema after being ... (fat) tissue. The results could change the paradigm for dealing with this debilitating, frequent ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology:
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):